Management of urinary tract infections from multidrug-resistant organisms.
Antibiotic resistance worsens clinical outcomes and, in some cases, significantly impacts the clinical management of urinary tract infections in the outpatient setting. This article presents the prevalence and mechanism of relevant antimicrobial resistance patterns encountered among uropathogens, and discusses the efficacy of antibiotic regimens and novel therapies in treating commonly encountered multidrug-resistant organisms.
Infectious Diseases, VA Boston HCS, 1400 VFW Parkway, West Roxbury, MA 02312, USA; Infectious Diseases, Boston University School of Medicine, Dowling 3 North Room 3104, Boston, MA 02115, USA. Electronic address: kalpana.gupta@va.gov.
Kalpana
K
Gupta
Section of Infectious Diseases, Boston Medical Center, Boston University School of Medicine, Dowling 3 North Room 3104, Boston, MA 02115, USA.
Nahid
N
Bhadelia
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019468:Disease Management; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000382:microbiology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents
Carbapenem-resistant Enterobacteriaceae; Cystitis; Extended-spectrum β-lactamases; Multidrug-resistant organisms; Vancomycin-resistant Enterococcus